As a group, sell-side analysts forecast that Integra LifeSciences will post 3.14 earnings per share for the current year.

Source: https://www.americanbankingnews.com/2023/10/03/integra-lifesciences-nasdaqiart-upgraded-by-stocknews-com-to-buy.html

Finally, Citigroup cut shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $59.00 to $39.00 in a report on Tuesday, May 23rd.

Source: https://www.americanbankingnews.com/2023/06/03/amalgamated-bank-buys-4825-shares-of-integra-lifesciences-holdings-co-nasdaqiart.html

Finally, Truist Financial increased their price target on Integra LifeSciences from $58.00 to $62.00 and gave the company a “hold” rating in a research note on Monday, April 17th.

Source: https://www.etfdailynews.com/2023/04/22/keybank-national-association-oh-takes-266000-position-in-integra-lifesciences-holdings-co-nasdaqiart/

JPMorgan Chase & Co. cut shares of Integra LifeSciences from a “neutral” rating to an “underweight” rating and decreased their price objective for the company from $56.00 to $43.00 in a report on Wednesday, May 24th.

Source: https://www.americanbankingnews.com/2023/06/03/amalgamated-bank-buys-4825-shares-of-integra-lifesciences-holdings-co-nasdaqiart.html